Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CGC-11047 + sunitinib
- Development stage
- Unknown
- Lead developer
- Cellgate
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
CGC-11047 + sunitinib is an investigational combination therapy involving two agents with distinct mechanisms of action. CGC-11047 is a polyamine analogue developed as an apoptosis stimulant, initially by Cellgate, and has been studied for its potential anticancer effects[3]. Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma (RCC), imatinib-resistant gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (pNET)[1][5][6][8]. Sunitinib works by inhibiting multiple receptor tyrosine kinases involved in tumor growth and angiogenesis, including platelet-derived growth factor receptors (PDGFRα/β), vascular endothelial growth factor receptors (VEGFR1/2/3), KIT, FLT3, CSF1R, and RET[5][6][8]. The combination has been evaluated in early-phase clinical trials to determine safety and dosing but does not have established efficacy or approval as a fixed combination[7].
- Brand names
- Sutent
- Other names
- sunitinib malate
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)Polyamine transporterODC1 (Ornithine decarboxylase)VEGFR4 (Vascular endothelial growth factor Receptor-3)CSF1R (Macrophage colony-stimulating factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)SAT1 (Spermidine/spermine N1-acetyltransferase 1)PDGFRB (Platelet-derived growth factor receptor beta)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)SMOX (Spermine oxidase)
Beyond the preview
Go deeper on CGC-11047 + sunitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CGC-11047 + sunitinib.